Edition:
India

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

10.98USD
23 Jul 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$10.98
Open
$10.98
Day's High
$11.03
Day's Low
$10.89
Volume
212,671
Avg. Vol
242,412
52-wk High
$19.48
52-wk Low
$9.14

Latest Key Developments (Source: Significant Developments)

Corcept Therapeutics says Received Paragraph IV Notice Letter Advising Sun Pharmaceutical Industries Submitted ANDA To U.S. FDA
Wednesday, 12 Jun 2019 

June 11 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING SUN PHARMACEUTICAL INDUSTRIES SUBMITTED ANDA TO U.S. FDA.CORCEPT - NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY SUN PHARMA'S PROPOSED PRODUCT, ARE INVALID AND/OR ARE UNENFORCEABLE.CORCEPT THERAPEUTICS - ABBREVIATED NEW DRUG APPLICATION SEEKS AUTHORIZATION FROM FDA TO MANUFACTURE, USE OR SELL GENERIC VERSION OF KORLYM IN U.S..  Full Article

Corcept Therapeutics Sees FY 2019 Revenue Of $285 Mln TO $315 Mln
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 GAAP EARNINGS PER SHARE $0.18.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.Q4 REVENUE $66.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $69.6 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.15 -- REFINITIV IBES DATA.REITERATED 2019 REVENUE GUIDANCE OF $285 - 315 MILLION.  Full Article

Corcept Therapeutics Reports Q4 Revenue $66.8 Mln
Friday, 1 Feb 2019 

Jan 31 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2019 REVENUE GUIDANCE.Q4 REVENUE $66.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.4 MILLION.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.2019 REVENUE GUIDANCE OF $285 - $315 MILLION.  Full Article

Judge Denies Teva Pharmaceuticals’ Motion To Dismiss Corcept Therapeutics’ Allegations Of Patent Infringement
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Corcept Therapeutics Inc ::JUDGE DENIES TEVA PHARMACEUTICALS’ MOTION TO DISMISS CORCEPT THERAPEUTICS’ ALLEGATIONS OF PATENT INFRINGEMENT.CORCEPT THERAPEUTICS INC - JUDGE WIGENTON'S DENIAL OF TEVA'S MOTION MEANS THAT CORCEPT'S LAWSUIT WILL PROCEED.  Full Article

Corcept Therapeutics Receives Orphan Designation For Relacorilant As Treatment For Pancreatic Cancer
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS RECEIVES ORPHAN DESIGNATION FOR RELACORILANT AS TREATMENT FOR PANCREATIC CANCER.CORCEPT THERAPEUTICS - FDA GRANTED ORPHAN DRUG STATUS TO CORCEPT'S SELECTIVE CORTISOL MODULATOR RELACORILANT TO TREAT PATIENTS WITH PANCREATIC CANCER.  Full Article

Corcept Therapeutics posts Q3 earnings per share $0.11
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q3 GAAP earnings per share $0.11.Q3 revenue $42.8 million versus I/B/E/S view $42 million.Q3 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $157 million to $162 million.  Full Article